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ABSTRACT
Background
Approaches to limiting exposure to antiretroviral therapy (ART) drugs are an active area of
HIV therapy research. Here we present longitudinal follow-up of a randomized, open-label,
single-center study of the immune, viral, and safety outcomes of structured therapy
interruptions (TIs) in patients with chronically suppressed HIV-1 infection as compared to
equal follow-up of patients on continuous therapy and including a final therapy interruption in
both arms.
Methods and Findings
Forty-two chronically HIV-infected patients on suppressive ART with CD4 counts higher than
400 were randomized 1:1 to either (1) three successive fixed TIs of 2, 4, and 6 wk, with
intervening resumption of therapy with resuppression for 4 wk before subsequent interruption,
or (2) 40 wk of continuous therapy, with a final open-ended TI in both treatment groups. Main
outcome was analysis of the time to viral rebound (.5,000 copies/ml) during the open-ended
TI. Secondary outcomes included study-defined safety criteria, viral resistance, therapy failure,
and retention of immune reconstitution.
There was no difference between the groups in time to viral rebound during the open-ended
TI (continuous therapy/single TI, median [interquartile range] = 4 [1–8] wk, n = 21; repeated TI,
median [interquartile range] = 5 [4–8] wk, n = 21; p = 0.36). No differences in study-related
adverse events, viral set point at 12 or 20 wk of open-ended interruption, viral resistance or
therapy failure, retention of CD4 T cell numbers on ART, or retention of lymphoproliferative
recall antigen responses were noted between groups. Importantly, resistance detected shortly
after initial viremia following the open-ended TI did not result in a lack of resuppression to less
than 50 copies/ml after reinitiation of the same drug regimen.
Conclusion
Cycles of 2- to 6-wk time-fixed TIs in patients with suppressed HIV infection failed to confer a
clinically significant benefit with regard to viral suppression off ART. Also, secondary analysis
showed no difference between the two strategies in terms of safety, retention of immune
reconstitution, and clinical therapy failure. Based on these findings, we suggest that further
clinical research on the long-term consequences of TI strategies to decrease drug exposure is
warranted.
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Antiretroviral therapy (ART) has been a milestone in the
treatment of HIV infection. Current treatment guidelines for
HIV-1 infection in the United States recommend the
initiation of ART in patients with CD4 T cell counts of less
than 350 cells/ll [1]. In implementing these guidelines, health-
care providers face the ongoing challenge of developing
treatment strategies that minimize drug-related toxicity and
adverse effects while retaining effective control of viral
replication. Furthermore, treatment-associated costs (partic-
ularly in resource-poor areas), difﬁculty in maintaining long-
term optimal adherence [2], and the emergence of viral
resistance [3,4,5] have limited the feasibility of life-long ART-
mediated viral suppression, increasing the need for alter-
native treatment strategies. Intermittent therapy strategies,
consisting of alternating cycles on and off ART, have
increasingly emerged as a potential intervention to address
limitations of continuous ART [6,7,8,9]. Therapy interruption
(TI) studies in ART-treated patients with suppressed HIV
infection [10] have addressed the general questions as to
whether such strategies can achieve greater viral control
through increased antiviral responses (autoimmunization
hypothesis) or simply serve as a strategy to reduce cost of
long-term therapy and drug-associated toxicity. While pilot
studies and uncontrolled (or incomplete) trials in patients
with chronic HIV infection have addressed viral and immune
outcomes of ﬁxed-length TI and ﬁxed on-drug cycles
[11,12,13,14,15,16], no completed randomized, controlled
trial has yet addressed by intent-to-treat analysis the outcome
during an open-ended TI of sequential TIs versus continuous
treatment in patients with conﬁrmed suppression. The largest
study to date in this area is the prospective single-arm Swiss–
Spanish Intermittent Trial (SSITT) conducted in 133
recruited patients undergoing sequential 2-wk TIs and
showing a lack of impact of this strategy on achieving
sustained viral loads of less than 5,000 copies/ml off therapy
in those that completed the study [11]. However, the lack of a
control arm in this study has left unanswered questions about
the impact of multiple TIs on time to rebound, immune
reconstitution, therapy failure, and viral resistance when
analyzed against a randomized control arm of continuous
treatment followed for equal time before a single open-ended
interruption.
We completed a randomized, controlled trial on the
outcome of repeated 2- to 6-wk TIs in patients with chronic
infection in which the comparator group maintained
continuous therapy and then an open-ended interruption
period was applied in both treatment groups. The study
addressed the potential for repeated interruptions of therapy
to delay time to viral rebound as a primary outcome and
analyzed secondary outcomes regarding study-deﬁned safety
criteria, viral suppression and resistance, and retention of
immune reconstitution.
Methods
Participants
Between August 2000 and December 2003, we enrolled 42
patients infected with HIV who were older than 18 y and on
ART; eligibility criteria included CD4 counts of greater than
400 cells/ll on ART with a nadir of no less than 100 cells/ll,
ART-mediated suppression (,500 copies/ml) for more than
6 mo and less than 50 copies/ml at recruitment on any
antiretroviral regimen. Approval of the study protocol was
obtained from the institutional review board (IRB) of the
Philadelphia Field Initiating Group for HIV Trials (Phila-
delphia, Pennsylvania, United States). Written informed
consent was obtained from all patients. Human experimen-
tation guidelines of the United States Department of Health
and Human Services and of the authors’ institutions were
followed. The study protocol, including the patient consent
form, the CONSORT form, and the IRB approval, can be
found in Protocols S1–S4.
Randomization and Study Design
Forty-two eligible patients from the Jonathan Lax Immune
Disorder Clinic in Philadelphia, Pennsylvania, were random-
ized via sealed envelopes in a 1:1 fashion to a ﬁrst phase
(phase I) of either (1) three successive TIs of 2, 4, and 6 wk,
respectively, or (2) maintenance of ART for 40 wk before a
ﬁnal interruption of therapy in both arms (phase II) subject
to therapy reinitiation criteria as described below. Phase II
consisted of an open-ended interruption to allow for
virological and immunological comparisons between the
groups off therapy. Study visits were every 2 wk for the
repeated interruptions group and every 4 wk for the
continuous ART group during phase I. Both groups were
followed every 2 wk during phase II. We followed a study
design with step-wise increases in the length of TI cycles to
address potential safety concerns (resuppression was con-
ﬁrmed after shorter TIs before longer interruptions were
initiated) and the hypothesis that sequential viral replication
intervals would stimulate viral control and a delay in time to
viral rebound.
Phase I procedures for the repeated interruptions group
included the following. (1) Interruption of therapy was
individually timed to occur after two HIV RNA measure-
ments of less than 50 copies/ml without any viral load
measurements greater than 400 copies/ml in between; these
interruptions increased from 2 to 4 to 6 wk sequentially. (2) If
a 0.5-log or greater reduction in viral load did not occur by 6
wk of reinitiated therapy or less than 50 copies/ml was not
achieved within 20 wk of reinitiated therapy, patients were
withdrawn as therapy failures and a resistance test was
performed. (3) Patients were also withdrawn as therapy
failures if (a) the CD4 cell number declined by more than
45% of the baseline CD4 count, (b) participants developed an
opportunistic infection, even if retaining required CD4 count
levels, or (c) a viral load of greater than 500,000 copies/ml
occurred once, with or without development of acute
retroviral syndrome as deﬁned by fever, skin lesions, and
pharyngitis.
Phase I procedures for the continuous therapy arm
included the following: (1) patient monitoring if detected
viremia was between 50 and 999 copies/ml, with the patient
withdrawn if their viral load did not return to less than 50
copies/ml immediately prior to phase II, and (2) patient study
withdrawal as therapy failure if during the 40-wk ART period
viral load rebounded to more than 1,000 copies/ml at two
consecutive time points.
Phase II procedures for both arms included the following:
(1) monitoring for patient study withdrawal criteria as
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point of a viral load greater than 5,000 copies/ml, (3)
monitoring until the time of therapy reinitiation at a viral
load greater than 30,000 copies/ml for three consecutive time
points, and (4) after reinitiation of therapy, follow-up on
therapy to conﬁrm resuppression to less than 50 copies/ml at
6, 10, and 14 wk on therapy. Clinical and laboratory
parameters (CD4 count and viral load) were monitored at
each visit, and venous blood was collected for additional
secondary outcomes during selected study visits.
In both phase I and II, participants taking non-nucleoside
reverse-transcriptase inhibitors (NNRTIs) were instructed to
stop them a day earlier than the remaining drugs in the
regimen.
Primary and Secondary Outcomes
The primary outcome was time to conﬁrmed virological
rebound during phase II. Rebound was deﬁned as ﬁrst time
point with greater than 5,000 copies/ml. Viral replication
magnitude as deﬁned by mean HIV-1 plasma RNA area under
the curve (AUCHIV RNA) was measured as a secondary
outcome at weeks 12 and 20 of phase II based on
reinitiation-of-therapy criteria outlined above.
Additional secondary outcomes included (1) safety out-
comes (serious adverse events [SAEs] and patient withdrawal
based on criteria deﬁned above), (2) retention of ART-
mediated immune reconstitution, and (3) detection of viral
resistance. Retention of immune reconstitution was analyzed
by (1) same-day whole blood ﬂow-cytometry-based analysis of
CD4 and CD8 T cells, including total and naı ¨ve (CD62 l/
CD45RA) and memory (CD45RO) subsets as described [17],
and (2) same-day recall response analysis of peripheral blood
mononuclear cell lymphoproliferative responses to Candida
albicans as described [17]. Viral resistance mutations were
retrospectively analyzed on cryopreserved plasma samples by
genotyping of ﬁrst available sample with viral load greater
than 100 copies/ml following each interruption using the
TruGene Assay (Visible Genetics, Toronto, Canada) at the
Gladstone Institute of Virology and Immunology (San
Francisco, California, United States) as previously described
[18,19].
Sample Size
The sample size required was calculated using PS [20]
software, and based on a type I error of 0.05, with 90% power,
to detect a difference of 4 wk or more in time to viral
rebound between arms. Eighteen patients per group resulted
in sufﬁcient power (18 for 90%, 13 for 80%) to determine a
difference of 4 wk or greater between groups in time to
rebound of virus during the open-ended interruption.
Assuming a loss to follow-up of 15%, we targeted 21 patients
per group, or 42 total.
Statistical Analysis
The primary analysis was an intent-to-treat analysis in
which dropouts were assigned a week 0 rebound time (e.g.,
maximum failure to delay rebound). In secondary analyses,
these dropouts were excluded. The log-rank test was used to
test the null hypothesis of no difference between arms in the
number of weeks from initiation of the open-ended TI to
reaching viral rebound as deﬁned. Patients not reaching end
point at 26 wk after the beginning of the open-ended TI
were censored. Wilcoxon rank sum tests were used to
compare baseline and week 0 of the open-ended interrup-
tion between groups. Wilcoxon signed rank tests were used
to test for no change from baseline to week 0 of phase II.
Finally, Wilcoxon rank sum tests were employed to test
between groups for equality of the mean AUCHIV RNA up to
12 and 20 wk. In all cases, a two-sided alpha level of 0.05 was
used to deﬁne statistical signiﬁcance. Unless otherwise
stated, results are presented as median (interquartile range)
in text and tables.
Results
Patient Flow and Discontinuations
Trial patient ﬂow is summarized in Figure 1. Between
August 2000 and December 2003, 42 patients at the
Jonathan Lax Immune Disorder Clinic at the Philadelphia
Field Initiating Group for HIV Trials were enrolled,
randomized, and followed as shown in Figure 2. In the
continuous therapy/single interruption arm, 16 of 21
patients reached the open-ended interruption. Reasons for
study discontinuation in this arm were loss to follow-up (n
= 1; patient moved away) and virological failure during
continuous therapy (n = 4; further discussed below). In the
repeated interruptions arm, 18 of 21 patients reached the
open-ended interruption following three TIs of 2, 4, and 6
Figure 1. Study Flow
DOI: 10.1371/journal.pmed.0010064.g001
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(50–2,590), 13,651 (180–222,589), and 18,887 (3,893–96,101)
copies/ml, respectively. Median time to less than 50 copies/
ml after resumption of therapy was 2 (0–4), 3 (1.8–12), and
9.5 (2–12) wk, respectively, with 9, 18, and 20 wk as the
maximum time needed to achieve suppression in 100% of
patients before reaching the open-ended interruption. Study
discontinuation in the repeated interruptions arm was due
to protocol violation (n = 1; patient restarted therapy
during interruption out of protocol), loss to follow-up (n =
1; patient imprisoned), and virological failure during on-
therapy period (n = 1; further discussed below).
Figure 2. Study Design (Phases I and II)
DOI: 10.1371/journal.pmed.0010064.g002
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The demographic and clinical characteristics of the two
groups at baseline are summarized in Table 1. Seventy-ﬁve
percent of participants were on their second to fourth
regimen while 25% were in their ﬁrst regimen. No sig-
niﬁcant difference was found in baseline parameters
between arms, with 33%–47% of patients on protease-
inhibitor-containing and 61%–71% on NNRTI-containing
regimens. Owing to the high participation of patients on
NNRTI-based regimens and concerns about TI and safety in
general, patient outcomes and treatment failure were
reviewed monthly by the IRB of this study during the ﬁrst
8 mo of study, quarterly for the following 4 mo, and semi-
annually thereafter. Figure 2 shows study design for both
arms, with a median follow-up of 41 (41–42) wk during
phase I for the continuous therapy/single interruption arm
and 42 (30–51) wk for the repeated interruptions arm.
Follow-up during phase II had a median duration of 27 wk
in both arms (continuous therapy/single interruption arm,
27 [8.75–47]; repeated interruptions arm, 27 [16.5–35]).
Following reinitiation of therapy after phase II, patients
suppressed viral replication to less than 50 copies/ml by a
median time of 10 (6–12) wk in both arms, excluding for two
patients in the continuous therapy/single interruption arm
who elected to stay off ART indeﬁnitely and one patient
from the repeated interruptions arm who reported non-
adherence following regimen reinitiation yet reached 52
copies/ml before withdrawing from additional follow-up.
Primary Outcome
An intent-to-treat analysis of the time to viral rebound
(.5,000 copies/ml) in the open-ended interruption showed
no difference between groups (continuous therapy/single TI,
median = 4 [1–8] wk, n = 21; repeated TI, median = 5 [4–8]
wk, n = 21; p=0.36). Figure 3 (top panel) shows the
probability of plasma HIV-1 RNA remaining less than 5,000
copies/ml for the two groups (n = 21 per group). Exclusion of
drop-outs in an as-treated analysis did not alter conclusions
(single TI, median = 5 [4–9] wk, n = 18; repeated TI, median
= 6 [4–8] wk, n = 16; p . 0.05). Additional secondary analysis
of the magnitude of viral load as shown in Figure 3 (second
panel) showed similar viral replication as determined by
mean AUCHIV RNA analysis at week 12 (single TI, median =
124,621 [23,326–262,348] AUCHIV RNA; repeated TI, median
= 100,400 [47,221–365,731] AUCHIV RNA; p . 0.05) or week 20
(single TI, median = 114,550 [31,829–362,628] AUCHIV RNA;
repeated TI, median = 153,097 [67,427–515,421] AUCHIV
RNA; p . 0.05).
Secondary Outcomes SAEs and patient discontinuation. No
patient discontinuation in either group was due to study-
deﬁned changes in CD4 cell count (reviewed further below)
or due to study-associated SAEs (disease progression or acute
retroviral syndrome). However, four non-study-related SAEs
occurred: two patients from the continuous therapy/single
interruption arm were hospitalized, one for a cholecystec-
tomy and one for acute rectal bleeding, during the 40-wk
ART period; a patient from the repeated interruptions arm
died of liver cancer during week 26 of the open-ended
interruption after previously reaching a viral load greater
than 5,000 copies/ml yet electing to stay off ART; and a
patient from the repeated interruptions arm developed a
transient ileitis.
Immune reconstitution. No signiﬁcant difference was ob-
served between groups in CD4 T cell counts at the start of
phase II, as illustrated in Figure 4. In addition, no difference
in the percentage of naı ¨ve CD4 cells or decrease of recall
response to C. albicans was observed, conﬁrming the absence
of signiﬁcant differences in the retention of baseline immune
reconstitution correlates between arms. However, a signiﬁ-
cant decrease in the abundance of CD4 cells relative to other
T cell types as summarized in CD4% (but not in absolute CD4
count ) was present in the repeated TI arm, corresponding to
a signiﬁcant increase in CD8 T cell count. In spite of
ﬂuctuations in CD4 T cell count levels between the start and
end of each monitored TI, a recovery of CD4 count levels was
achieved upon resuppression following each TI in conjunc-
tion with a retention of lymphoproliferative responses
against C. albicans before, during, and after each TI, as
illustrated in Figure 5.
Viral resistance mutations and therapy failure. An intent-
to-treat analysis of the combined number of patients per arm
with detected resistance mutations irrespective of therapy
failure in phase I and during the ﬁnal TI in phase II showed
no signiﬁcant difference between arms (continuous therapy/
single TI, 7/21; repeated TI, 10/21; p . 0.05).
Study-deﬁned criteria for therapy failure of a previously
suppressive regimen were met by 4/21 patients in the
continuous therapy/single interruption arm (patients S37,
S47, S52, and S59) in association with self-reported non-
adherence to therapy and detection of resistance mutations
in phase I, as listed in Table 2. One patient in the repeated
interruptions arm (1/21; patient S56) failed therapy after 20
wk following the third TI by maintaining a viral load between
Table 1. Baseline Demographic and Clinical Characteristics per Study Arm
Characteristics Continuous Therapy/
Single Interruption
Group (n = 21)
Repeated Interruptions
Group (n = 21)
Age (years)
(median [25%, 75% quartiles])
42 (38.5, 42) 46 (41.5, 53)
Male 81% 100%
Ethnicity 42% AA, 48% C, 10% H 14% AA, 81% C, 5% H
Route of infection 90% S, 10% IV 95% S, 5% IV
Years since diagnosis 7 (5, 11.5) 11 (6.5, 15.5)
(median [25%, 75% quartiles])
Years on ART 4.5 (4, 6.7) 7 (6, 11)
(median [25%, 75% quartiles])
CD4þ T cell count
at recruitment (cells/mm
3)
(median [25%, 75% quartiles])
637 (481, 793) 658 (506.5, 815.8)
Follow-up period (weeks)
(median [25%, 75% quartiles])
79 (59, 88.5) 81 (67, 88.5)
Drug classes used at entry
a
PI 7/21 10/21
NNRTI 15/21 13/21
a Numbers include cases of PI/NNRTI combined use at study entry.
AA, African American; C, Caucasian; H, Hispanic, IV, intravenous drug usage; PI, protease inhibitor; S, sexual
transmission.
DOI: 10.1371/journal.pmed.0010064.t001
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tected resistance mutations.
In patients who reached phase II in the absence of therapy
failure, a total of 12 patients were identiﬁed to have
resistance mutations at the ﬁrst viremic time point (contin-
uous therapy/single TI, 3/16; repeated TI, 9/18; p=0.06). A
greater number of resistance mutations was detected in the
repeated interruption arm, as summarized in Table 3. In ten
out of these 12 patients, a change in resistance patterns was
observed when comparing the ﬁrst viremic time point to the
last. All 11 of 12 patients in Table 3 who reinitiated therapy
retained suppressive ability of their respective regimens, as
did all other patients who did not show resistance mutations
in phase II. In the repeated interruptions arm, analysis of
newly detected resistance mutations in phase II, as deﬁned by
a lack of detection during viremic time points in phase I,
identiﬁed 3/18 patients (patients S4, S22, and S43) with this
pattern (see notations in Table 3).
Discussion
Earlier reports on TI strategies in patients with chronic
HIV infection include multiple pilot or single-arm study
designs centered on the effects on viral control by compar-
ison with pre-therapy periods, detection of resistance
mutations without parallel follow-up of a continuously
treated arm, and inclusion of variable criteria regarding viral
resuppression before proceeding with repeated TIs
[11,12,14,16]. In contrast, our strategy mandated resuppres-
sion of viral replication to less than 50 copies/ml before each
TI and presents the ﬁrst comparison of viral replication
Figure 3. Lack of a Difference between Groups in Plasma HIV-1 RNA during Phase II
Top panel shows Kaplan-Meyer plot summarizing time to a viral load of more than 5,000 copies/ml in both arms. Second panel shows viral load
(mean 6 standard error) per arm during 27 wk of TI (median time of phase II). Bottom table shows number of patients at time points shown for
viral load in the second panel; the decrease in viral load over time is due to the reinitiation of therapy in patients with higher viral loads.
DOI: 10.1371/journal.pmed.0010064.g003
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patients randomized to complete three sequential TIs or stay
under continuous therapy. Our data, based on intent-to-treat
analysis, did not show that repeated TIs resulted in a clinically
signiﬁcant virological beneﬁt as measured by the time to viral
rebound to more than 5,000 copies/ml (see Figure 3).
Secondary as-treated analysis on viral replication magnitude
also indicated a lack of difference between arms. Consistent
with the ﬁndings of SSITT [11], analysis of our data by the
categorical classiﬁcation of a ‘‘responder’’ as a patient with
viral load less than 5,000 copies/ml at week 12 off therapy
showed no signiﬁcant difference in this frequency between
arms (single TI, 5/18; repeated TI, 5/16), suggesting the
presence of ‘‘responders’’ irrespective of previous protocol-
mandated TIs.
Based on secondary outcome measures, the incidence of
adverse events (SAEs, therapy failure, and patient discontin-
Figure 4. T Cell Subsets and Recall Lymphoproliferative Response at the
End of Phase I
End of phase I values for each arm are summarized (median and ﬁrst
and third quartiles) in the stacked ﬁgures showing from top to
bottom: CD4 T cells/ll, CD4%, CD4
 CD45RA
þCD62L
þ%( n a ı ¨ve
phenotype), CD8 T cells/ll, CD8%, and C. albicans lymphoproliferative
response (shown as stimulation Index, SI). Unpaired p values for each
variable are shown above corresponding bracket.
DOI: 10.1371/journal.pmed.0010064.g004
Figure 5. CD4 T Cells/ll and T Cell Recall Lymphoproliferative Response
during Sequential TIs in Phase I
Shown are data from the repeated interruptions arm. Panels show the
TI initiation visit and TI end visit of each sequential TI inclusive of
the initiation visit for phase II (open-ended TI).
DOI: 10.1371/journal.pmed.0010064.g005
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count on therapy or opportunistic infections) was not
observed to be different between arms. Prospective safety
outcomes in our study are in accordance with reports from a
retrospective analysis of 1,290 patients who interrupted
treatment at least once (,3 mo) without an increased risk
of HIV-associated morbidity or mortality (with the exception
of patients in Center for Disease Control and Prevention
stage C during ﬁrst interruption only) [21]. In regards to
immunological outcomes, a concern associated with inter-
ruption of suppressive therapy is the potential for irrever-
sible, viral-mediated CD4 T cell loss leading to disease
progression [6,22]. We did not observe a decrease in CD4
cell numbers or lymphoproliferative responses against C.
albicans when measured between arms before the open-ended
TI (see Figure 4), nor following resuppression after moni-
tored TI reinitiation cycles in the repeated interruptions arm
(see Figure 5). The latter is consistent with observations by
others and does not support an immediate immunological
‘‘cost’’ to short-term TIs [12,14,15,16,23]. However, we do
show that monitoring CD4 cell numbers by percentage could
lead to misinterpreting a signiﬁcant loss of CD4 cells as a
result of a signiﬁcant increase in CD8 count following TIs,
even though absolute CD4 count numbers remained un-
changed (see Figure 4). Interestingly, the increase in CD8 T
cell number also corresponded with an increase in HIV-
speciﬁc responses as measured by interferon-gamma expres-
sion (data not shown), which in light of an absence of effect
on viral load between arms further supports that TI strategies
Table 2. Therapy Failures with Plasma HIV-1 Protease and Reverse Transcriptase
Inhibitor–Associated Resistance Patterns during on Therapy Periods (Study Phase I)
Group Patient Drug
Regimen
a
Protease Reverse
Transcriptase
Suppression/
Resuppression
on Regimen
Continuous
therapy
S37 ddI,
d4T,
3TC,
EFZ
M46I,
I54V,
L63P,
I84V
D67N
a,
K70K/R
a,
K103N
a,
T215NTYS
a
No
S47 ddI,
d4T,
EFZ
None D67N
a,
V179D,
K219Q
a
No
S52 d4T,
3TC,
EFZ
None M184V
a,
K103N
a
No
S59 ABV,
d4T,
EFZ
None K103K/N
a No
Repeated
interruptions
S56 ddI,
d4T,
NVP
None D67N/D
a,
K70R
a,
K103K/N
a,
G190A
a
No
Bold identifies drugs for which mutations were detected in plasma.
3TC, lamivudine; ABV, abacavir; ddI, didanosine; d4T, stavudine; EFZ, efavirenz; NVP, nevirapine; RT, reverse
transcriptase.
a Mutations associated with patient’s regimen.
DOI: 10.1371/journal.pmed.0010064.t002
Table 3. Non-Therapy Failures with Resistance Detected off ART at First and Last Viremic Time Point in Comparator Open-Ended TI (Phase II)
Group Patient Drug Regimen
at Interruption
First Viremic Time Point Last Viremic Time Point Resuppression
on Regimen
Protease RT Protease RT
Continuous therapy/
single interruption
S13 IDV, RTV, ZDV, 3TC None M184M/V
a None None Stayed off ART
S32 d4T, 3TC, EFZ None K101K/Q
a None None Yes
S40 IDV, RTV, d4T None K70K/R
a None K70K/R
a Yes
b
Repeated
interruptions
S4 IDV, RTV, d4T, 3TC None K219E
a,c None None Yes
S7 IDV, RTV, d4T, 3TC None K70R
a None K70R
a Yes
b
S19 ddI, 3TC, EFZ None K103N
a None K103K/N
a Yes
S22 NLF, ddI, NVP None M41L
c, M184M/V
a None None Yes
S23 ddI, d4T, EFZ L90M/L, L63P,
G73TSAG
M184M/V
a None None Yes
S35
d LOP, RTV, ABV, EFZ L10I/L, L24I/L,
M46M/L,
L63P
a, A71T/A
a,
V82A/V
a
M41L
a, E44E/D,
D67N
a,T 6 9 D
a,
Y181C
a, L210W
a,
M184V, T215C
None M41M/L
a, E44E/D,
D67N
a, T69NTDA
a,
T215Y
Yes
b
S43 ddI, d4T, EFZ None M41L
a, K103N
a,c,
M184V, T215Y
None M41M/L
a, T215NTYS Yes
S45
e NLF, d4T, 3TC None D67N/D
a,c, K70K/R
a,c,
M184V
a,c,
K219Q
a,c,
None M184M/V
a, K219K/Q
a Yes
e
S51 NLF, d4T, 3TC None M184M/V
a None None Yes
Bold identifies drugs against which mutations were detected.
a Mutations associated with patient’s regimen.
b Patient/physician changed regimen after open-ended interruption for reasons not related to suppression activity on previous regimen: patient S7 changed to 3TC, TNV, EFZ, NVP; patient S40 changed to LOP, RTV, ddI, TNV; and patient S35
changed to LOP, RTV, ABV, TNV.
c Mutations not detected at the first plasma HIV-1 RNA tested during prior TIs.
d Resistance shown for patient S35 is last available, at week 2 of the third TI.
e Patient S45 was lost to follow-up after the end of the third TI. Resistance shown is last available, at week 6 of the third TI. Resuppression noted after completion of the third TI.
3TC, Lamivudine; ABV, Abacavir; d4T, Stavudine; ddI, Didanosine; EFZ, Efavirenz; LOP, Lopinavir; NLF, Nelfinavir; NVP, Nevirapine; TNV, Tenofovir; ZDV, Zidovudine.
DOI: 10.1371/journal.pmed.0010064.t003
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between viral replication and host antiviral responses
[14,16,23,24].
Importantly, no evidence for an increase of viral resistance
in association with therapy failure was present in the
repeated interruptions arm (See Table 2). We did not observe
a greater clinical failure of NNRTI-based regimens in the
repeated interruption arm due to ‘‘single drug’’ periods as
predicted by recently redeﬁned drug half-life estimates and
the presence of viral replication during each interruption
[25,26,27]. However, the percentage of patients with resist-
ance mutations detected in this study in the repeated
interruption arm (47%) is higher than the 17% observed in
the SSITT cohort [11], in which patients with prior treatment
failures were excluded [28]. We interpret this difference to
mean that the resistance detected off drug in both our and
their cohorts is likely associated with the greater number of
drug-experienced patients in our cohort (75%) and the
detection of prior archived resistance mutations as supported
by Metzner et al. [29], who documented in 14/25 (56%) SSITT
patients the presence of minor populations of M184V
occurring at least once off drug during interruption of
therapy.
In spite of the lack of difference in the total number of
patients with resistant mutations detected on therapy during
phase I and off therapy in phase II (7/21 [33%] versus 10/21
[47%], respectively) in both arms, we do report in similarity
to others a greater detection of resistance mutations in the TI
arm when restricting analysis to the last off-drug period only
[29,30] as three of 16 (18%) had mutations detected off drug
in the continuous therapy/single interruption arm compared
to nine of 18 (50%) in the repeated interruption arm.
However, based on the lack of association between viral
resistance detected off-drug shortly after TI and resuppres-
sion by the same regimen in all patients, it remains
undetermined to what extent TIs favor the detection of
archived mutations in chronically suppressed patients and to
what extent these mutations are a signal for a future therapy
failure. The latter is best exempliﬁed by the data we collected
on patients on NNRTI-based regimens in the repeated
interruptions arm where two patients (S19 and S43) showed
K103N detection (only during the off-drug periods) in the
absence of therapy failure while maintaining the same
regimen after each TI, including post-study follow-up (Table
S1). On the other hand, virological failure in the continued
presence of an NNRTI-based regimen in phase I was
associated with detection of K103N, as observed in one
patient (S56) in the repeated interruption arm and three
patients (S37, S52, and S59) in the continuous therapy arm
with self-reported non-adherence.
Drug resistance that occurs during virological drug failure
predicts virological responses to salvage treatment [31,32,33].
In contrast, the clinical implications of drug resistance
mutations that appear shortly after TI in chronically sup-
pressed patients are not clear. Case reports in this cohort of
patients have demonstrated that drug-resistant variants that
appeared during TIs may not persist in subsequent time
points even after repeated use of the same antiretroviral
regimen [19,34]. We now observe that drug resistance
appearing during TIs can be transient since 50% and 33%
of patients listed in Table 3 showed complete and partial
reversion to wild type, respectively, when comparing to
resistance at the last available viremic time point in phase II
(See Table 3). Further, we observed durable resuppression of
plasma viral RNA level in many patients who had drug-
resistance mutations off therapy that would otherwise be
expected to affect part of their treatment regimen when
reinitiated (see Table S1). Virus populations that expand
shortly after TI may lack all of the adaptations required to
achieve high levels of plasma viremia in the presence of drug
during continuous treatment. These adaptations may include
the resistance-associated mutations, which were detected, as
well as secondary mutations that may increase the viral
replication capacity [35,36] or envelope adaptations required
to escape concurrent humoral immune responses [37,38]. It is
of interest to note that despite the large amount of research
activity on TIs in patients with suppressed chronic infection
and the hundreds of monitored interruptions studied to date,
only limited cases of development of clinical resistance (as
evidenced by a lack of viral resuppression following therapy
reinitiation) have emerged, in contrast to the multiple
reports of detection of viral sequences off ART associated
with resistance as shown in this study and others
[11,19,29,30,39,40].
Taken together, while our data show no clinically signiﬁ-
cant beneﬁt for repeated TIs of less than 1.5 mo in patients
with CD4 counts greater than 400 on therapy with regard to
viral control as deﬁned by time to rebound, secondary
outcomes document no signiﬁcant difference in levels of
retention of immune reconstitution between arms and no
increased incidence of virological failure as a consequence of
TIs. While our data indicate that this TI strategy should not
be pursued outside of a clinical trial setting, we argue that it
will be important to collect additional data on the potential
beneﬁts of drug-sparing regimens (such as reduced long-term
toxicity and reduced cost) and to deﬁne long-term outcomes
in comparison with continuous therapy.
Supporting Information
Registration of randomized trial at clinicaltrials.gov under identiﬁer
NCT00051818.
Protocol S1. Protocol Text: Effects of Sequential TI
Found at DOI: 10.1371/journal.pmed.0010064.sd001 (614 KB DOC).
Protocol S2. Study IRB Approval
Current IRB approval for study at clinical site.
Found at DOI: 10.1371/journal.pmed.0010064.sd002 (179 KB PDF).
Protocol S3. Wistar IRB Approval
IRB approval to receive study biological material at the Wistar
Institute for research.
Found at DOI: 10.1371/journal.pmed.0010064.sd003 (201 KB PDF).
Protocol S4. CONSORT Checklist
Found at DOI: 10.1371/journal.pmed.0010064.sd004 (50 KB DOC).
Table S1. Patients with Detected Resistance during Phase II: Regimen
at Initiation of Phase II and Subsequent Post-Study Follow-Up to
August 2004
Found at DOI: 10.1371/journal.pmed.0010064.st001 (36 KB DOC).
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Patient Summary
Why Was This Study Done? Highly active antiretroviral therapy has
revolutionized HIV treatment for patients who have access to the
medications. But the drugs are expensive, have side effects, and can
become ineffective when the virus develops resistance. Structured
treatment interruptions (STIs), also known as ‘‘drug holidays’’ (because
patients take a holiday from their drugs), have been suggested as
possible alternatives to continuous therapy. Initially, there was fear that
patients who went back on therapy after an interruption would not be
able to control the virus again, but there was also hope that STIs might
actually strengthen the immune system. In addition, STIs might alleviate
some side effects, and they would certainly reduce costs. This study uses
a particular design to examine the risks and benefits of STIs.
What Did the Researchers Do? The researchers studied 42 patients who
received either continuous therapy for 40 weeks or three successive
treatment interruptions of two, four, and six weeks, followed by a final
open-ended interruption for both groups. The researchers then recorded
how long patients were able to control the virus before their viral load
reached a certain threshold and they had to restart therapy. They also
examined CD4 counts and therapy failure, and looked for resistant
viruses on and off therapy.
What Did They Find? In terms of being able to control the virus, it made
no difference whether patients were on continuous therapy or had three
STIs. In other words, when both groups stopped treatment at 40 weeks,
the length of time that the patients could control the virus was the same
in both groups. Eventually, all patients (except two who elected to stay
off antiretroviral therapy) re-initiated therapy because of a rising viral
load, and the patients once on therapy all regained control over the
virus. Resistant viruses were found in patients from both groups, but
during the final interruption they were more common in the group that
had received the three STIs.
What Does This Mean? The study confirms that STIs do not help with
viral control, consistent with other studies that found that STIs had no
clinical benefit. On the other hand, no short-term adverse events were
present, as all patients were able to regain control over the virus after
they went back on treatment (without a drop in CD4 count), even after
several rounds of interruptions and tests to detect of resistant viruses.
There remains concern about whether recurrent cycles of viral replication
and suppression might in themselves be harmful, and whether the
presence of resistant virus is a signal for future treatment failure. Given
these unanswered questions, STIs should only be undertaken within
clinical trials.
What Next? Possible risks and benefits of STIs in the management of
therapy remain an active area of research. Evidence so far has not shown
clinical benefits. Ongoing studies need to clarify whether there are long-
term risks (and what they are), so that we can weigh these against the
benefits of reducing costs and side effects.
Additional Online Information
The Body information Web page on STIs: http://www.thebody.com/
treat/sti.html
Information on ‘‘continuing antriretroviral treatment’’ from AVERT, an
international HIV and AIDS charity based in the United Kingdom: http://
www.avert.org/conttrt.htm
Information on STIs from NAM, a United Kingdom registered charity:
http://www.aidsmap.com/en/docs/7980314C-97B5–412F-93B1-
AD8B64F51F73.asp
Factsheet on HIV treatments from the United States National Institute for
Allergy and Infectious Diseases: http://www.niaid.nih.gov/factsheets/
treat-hiv.htm
Search results from Clinicaltrials.gov when searching for ‘‘HIV’’ and
‘‘treatment interruption’’ combined terms: http://www.clinicaltrials.gov/
search/term=%22TreatmentþInterruption%22%5BCONDITION%5DþAND
þHIVþ%5BCONDITION%5D
PLoS Medicine | http://www.plosmedicine.org December 2004 | Volume 1 | Issue 3 | e64 228
Therapy Interruption in Chronic HIV